Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.35 |
| ▸ | DRD4 | P21917 | 1/20 | 0.34 |
| ▸ | CASP6 | P55212 | 1/20 | 0.34 |
| ▸ | GFER | P55789 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | RAD52 | P43351 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8723002 | 0.99 | SLC6A9 (0.38) | SLC6A9HSD17B10LMNAMAPTS1PR1 | |
| SCHEMBL8722452 | 0.94 | MAPT (0.37) | SLC6A9HSD17B10LMNAMAPTS1PR1 | |
| SCHEMBL8723014 | 0.86 | MAPT (0.36) | LMNAMAPTDRD4CASP6GFER | |
| SCHEMBL8722456 | 0.85 | RAD52 (0.37) | LMNAMAPTCASP6GFERALDH1A1 | |
| Hydrochloric Acid SCHEMBL8719317 | 0.84 | RAD52 (0.36) | LMNAMAPTCASP6GFERALDH1A1 | |
| Hydrochloric Acid SCHEMBL8722394 | 0.82 | SLC6A9 (0.30) | SLC6A9 | |
| SCHEMBL8723022 | 0.81 | CASP6 (0.33) | MAPTCASP6GFERALDH1A1 | |
| SCHEMBL6320212 | 0.81 | LMNA (0.44) | HSD17B10LMNAMAPTCASP6GFER | |
| SCHEMBL4581605 | 0.80 | MAPT (0.42) | LMNAMAPTALDH1A1 | |
| Tetraxetan SCHEMBL861961 | 0.80 | SLC6A9 (0.49) | SLC6A9HSD17B10LMNAMAPTS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | claimed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | claimed |
| EP-0543482-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 1993-05-26 | — | — | EP | claimed |
| US-7351389-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2008-04-01 | — | — | US | disclosed |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-28 | — | — | US | disclosed |
| US-6875864-B2 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 2005-04-05 | — | — | US | disclosed |
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO SUISSE SA (CH) | 2003-09-11 | — | — | US | disclosed |
| EP-0543482-B1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INT BV (NL) | 2002-02-06 | — | — | EP | disclosed |
| EP-0814849-A1 | MAGNETICALLY LABELED CHEMOATTRACTANTS AS TARGETED CONTRAST AGENTS IN THE NMR IMAGING OF LIVING TISSUES | BRACCO International B.V. (NL) | 1998-01-07 | — | — | EP | disclosed |
| WO-1997014443-A1 | MAGNETICALLY LABELED CHEMOATTRACTANTS AS TARGETED CONTRAST AGENTS IN THE NMR IMAGING OF LIVING TISSUES | BRACCO INTERNATIONAL B.V. (NL) | 1997-04-24 | — | — | WO | disclosed |
| EP-0543482-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | BRACCO INTERNATIONAL B.V. (NL) | 1993-05-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030171561-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | ARGLU1, PRMT1, AADAC | SLC6A9 1383/4885HSD17B10 4364/4885LMNA 3524/4885 |
| US-20050090689-A1 | Aminocarboxylate ligands having substituted aromatic amide moieties | AADAC, ANXA3, AAAS | SLC6A9 1443/4885HSD17B10 4486/4885LMNA 2658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.